CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum
2006

CHEK2 1100delC in Breast and Colorectal Cancer Patients

Sample size: 75 publication Evidence: low

Author Information

Author(s): Anna Isinger, Misha Bhat, Ake Borg, Mef Nilbert

Primary Institution: Lund University

Hypothesis

Is the CHEK2 1100delC mutation a significant contributor to double primary breast and colorectal cancer?

Conclusion

The CHEK2 1100delC mutation is not a major cause of double primary breast and colorectal cancer in Sweden.

Supporting Evidence

  • 2.5% of the patients carried the CHEK2 1100delC mutation.
  • The mutation frequency in the control group was 1%.
  • The study analyzed 75 patients with metachronous tumors.

Takeaway

This study looked at women with both breast and colorectal cancer to see if a specific gene mutation was causing their cancers, but it turns out that it probably isn't.

Methodology

The study used a population-based cancer registry to identify patients and sequenced tumor material to assess the CHEK2 1100delC mutation.

Limitations

The small sample size limits the strength of the findings.

Participant Demographics

Women diagnosed with both breast and colorectal cancer.

Statistical Information

P-Value

0.26

Statistical Significance

p = 0.26

Digital Object Identifier (DOI)

10.1186/1471-2407-6-64

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication